Unidade Local De Saude De Amadora Sintra E.P.E.
- Address
- lock Available on a paid plan
Nephrology and Kidney Disease Research
At Unidade Local De Saude De Amadora Sintra E.P.E., the Serviço de Nefrologia is involved in studies focused on immune system diseases and male and female urogenital conditions, with a strong emphasis on kidney disease. Research includes focal segmental glomerulosclerosis and related proteinuric disorders, aiming to evaluate new treatments that may reduce kidney damage and improve long-term renal outcomes.
- Studies in focal segmental glomerulosclerosis and other protein-losing kidney disorders
- Research on treatment options designed to lower proteinuria and protect kidney function
- Clinical evaluation of therapies for chronic renal conditions linked to immune-mediated disease
This work reflects the site’s broader interest in improving care for patients with complex nephrology conditions through new therapeutic approaches.
Breast Cancer and Oncology Trials
A major part of the research portfolio at this hospital centers on neoplasms, especially breast cancer. Trials are studying early and advanced disease across ER-positive, HER2-positive, HER2-low, and triple negative breast cancer, with the goal of improving recurrence prevention, disease control, and treatment effectiveness.
- Research in early-stage and metastatic breast cancer
- Studies testing new cancer therapies and combinations to improve survival and delay progression
- Trials aimed at preventing recurrence and refining treatment choices for different tumor subtypes
The oncology program also includes studies in ovarian cancer and other advanced solid tumors, supporting a broad effort to improve outcomes in difficult-to-treat cancers.
Respiratory and Lung Disease Studies
The site is also active in respiratory tract diseases, with trials in severe asthma, metastatic non-small cell lung cancer, and interstitial lung disease secondary to systemic sclerosis. These studies are designed to better control symptoms, assess lung function, and explore new options for both chronic inflammatory and cancer-related lung conditions.
- Asthma research focused on improving symptom control and reducing flare-ups
- Studies in non-small cell lung cancer examining new treatment strategies
- Investigation of systemic sclerosis-related interstitial lung disease to support breathing and preserve lung capacity
This respiratory research adds an important dimension to the site’s clinical trial activity in chronic and advanced lung diseases.
Autoimmune and Immune-Mediated Disease Research
Another key area is immune system diseases, especially systemic lupus erythematosus. Trials are evaluating whether new therapies can better reduce disease activity and support long-term safety in patients living with this complex autoimmune condition.
- Studies in systemic lupus erythematosus focused on disease control and treatment safety
- Research aimed at reducing immune-driven inflammation and improving quality of life
- Ongoing evaluation of long-term treatment tolerability in chronic autoimmune disease
This work highlights the site’s interest in therapies that may offer more durable benefit for patients with persistent inflammatory disease.
Cardiovascular and Metabolic Research
The clinical trial program at Unidade Local De Saude De Amadora Sintra E.P.E. includes cardiovascular diseases and type 2 diabetes, with studies looking at stroke prevention, heart failure risk, and broader cardiovascular protection in people with metabolic disease. These trials aim to improve outcomes in patients at elevated risk of serious heart and vascular events.
- Trials in stroke prevention after acute ischemic events
- Research in type 2 diabetes with and without established cardiovascular disease
- Studies evaluating whether new treatment strategies can lower major cardiovascular complications
This therapeutic area links metabolic care with vascular risk reduction, an important focus for patients with long-term chronic disease.
Infectious Disease and HIV Research
The site also contributes to virus diseases research, including HIV-1 infection. These studies are exploring new treatment approaches for people who have not yet received therapy, with the aim of improving viral control and simplifying care.
- Studies in HIV-1 infection for treatment-naive patients
- Research focused on evaluating new antiviral options and treatment convenience
- Clinical work supporting better long-term management of chronic viral disease
This area broadens the site’s research profile beyond specialty medicine into important infectious disease care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 11 therapeutic areas and 15 of 80 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 63 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
- 1AstraZeneca AB2active
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +8 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 84 other sites in Portugal
Therapeutic Area Benchmark — Portugal
Select a therapeutic area to compare against other sites in Portugal.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Portugal
Market Share
Country: Portugal
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Unidade Local De Saude De Amadora Sintra E.P.E.
lock Showing 1 of 29 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants with Active Systemic Lupus Erythematosus (SLE) (POETYK SLE-2) | Bristol-Myers Squibb Services Unlimited Company | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 80 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Letrozole | 5 | Unknown | 2017-07-06 | 2025-06-30 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.